Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
98M
-
Number of holders
-
37
-
Total 13F shares, excl. options
-
34.7M
-
Shares change
-
+16.9M
-
Total reported value, excl. options
-
$72.8M
-
Value change
-
+$35.3M
-
Put/Call ratio
-
0.48
-
Number of buys
-
25
-
Number of sells
-
-16
-
Price
-
$2.10
Significant Holders of aTYR PHARMA INC - COMMON STOCK (ATYR) as of Q1 2023
49 filings reported holding ATYR - aTYR PHARMA INC - COMMON STOCK as of Q1 2023.
aTYR PHARMA INC - COMMON STOCK (ATYR) has 37 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34.7M shares
of 98M outstanding shares and own 35.37% of the company stock.
Largest 10 shareholders include FEDERATED HERMES, INC. (10.2M shares), FMR LLC (7.97M shares), Stonepine Capital Management, LLC (4.83M shares), Alyeska Investment Group, L.P. (2.47M shares), Tikvah Management LLC (2.46M shares), VANGUARD GROUP INC (2.09M shares), Samsara BioCapital, LLC (1.75M shares), CVI Holdings, LLC (589K shares), GEODE CAPITAL MANAGEMENT, LLC (579K shares), and BlackRock Inc. (329K shares).
This table shows the top 37 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.